Cancer patients who belong to the Black and Hispanic communities are more likely to be infected with coronavirus disease 2019, than white patients, according to findings from a study presented at the American Society of Clinical Oncology’s (ASCO) Quality Care Symposium, which took place virtually on October 9-10, 2020.

Robert S Miller, Medical Director for CancerLinQ, said in an official release: “Patients with cancer are, unfortunately, faced with balancing cancer treatments with the risk of developing Covid-19. This research, while preliminary, will hopefully help patients and providers understand who’s most at risk of Covid-19 and plan cancer treatment accordingly.”

For the study, the researchers used data from ASCO’s CancerLinQ (CLQ) Discovery database.

Also read: Pfizer modifies protocol for virus vaccine study

The researchers identified cancer patients, who had either a positive test for SARs-CoV-2 or a diagnosis code of Covid-19, from the electronic health records data of the CancerLinQ Discovery

Read More

PASADENA, MD — Nobody is invincible, not even Nicholas Patrick. Years ago, the Anne Arundel County resident felt discomfort below the belt and decided to get it checked out.

Patrick thought it would be a quick fix, nothing that an antibiotic couldn’t solve. He was wrong.

“When you’re 27 years old, you don’t expect somebody to say the word ‘Cancer’ to you,” Patrick said. “It was a terrifying experience.”

Through that horror, Patrick found a drug that changed his world: CBD. The cannabis-derivative relaxes its users without giving them a high.

The compound helped Patrick claw through chemotherapy and eventually open Pasadena’s newest CBD shop. Before Patrick, now 35, became a multi-store business owner, he had to fight through the pain.

Patrick was diagnosed with stage 2 testicular cancer in July of 2012. The disease knocked him into a scary place. He lived with his mother, had a 5-year-old son

Read More

From Women’s Health

  • Kate Hudson, 41, just showed off her abs in a pink underwear set on Instagram.

  • She shared the photo to raise awareness for Kit Undergarments’ initiative donating money to breast cancer research.

  • Kit is donating $1 to Women’s Cancer Research Fund for every post with #kitstokickcancer.

Underwear pics are pretty much a guaranteed way to grab attention on Instagram, but Kate Hudson just shared a snap with a twist: She’s posting it to help raise money for breast cancer research.

In a new post, the 41-year-old Fabletics co-founder is jumping into the air with her hands over her head. She’s wearing a pretty pink bra and high-waisted underwear set—and oh yeah, her abs look amazing.

“It’s breast cancer awareness month and I’m joining my friends @kitundergarments company to #kitstokickcancer 🎀,” the actress wrote in the caption. “Sending a HUGE hug to all the survivors, the fighters and

Read More

Gilead (GILD) has nailed HIV and HCV. It has long striven to build a powerful cancer franchise. Its adventurings in the thicket of cancer therapeutics during the early years of this decade have been painful to watch. Gilead’s 2017 Kite Pharma acquisition marked a break from its earlier efforts; it has its attractions, but is challenging to scale, as I will discuss. Gilead’s flurry of even more recent oncology deals shows a hearty appetite but a questionable palate.

The thesis of this article is that despite Gilead’s longstanding record of successes in so many endeavors, it has fallen well short of the mark in terms of building a commercially attractive cancer portfolio. This has not been for lack of effort, as I will show.

This article does not discuss Gilead’s 9/13/20 Immunomedics (IMMU) deal, which has strong coverage in several recent Seeking Alpha articles. It should, however, serve as a

Read More



a close up of a person talking on a cell phone: U.S. Representative Katie Porter (D-CA) speaks at a campaign town hall meeting with Democratic 2020 U.S. presidential candidate and U.S. Senator Elizabeth Warren (D-MA) in Mason City, Iowa, U.S., January 11, 2020. Brian Snyder/Reuters


© Brian Snyder/Reuters
U.S. Representative Katie Porter (D-CA) speaks at a campaign town hall meeting with Democratic 2020 U.S. presidential candidate and U.S. Senator Elizabeth Warren (D-MA) in Mason City, Iowa, U.S., January 11, 2020. Brian Snyder/Reuters

  • Rep. Katie Porter tore into Celgene CEO Mark Alles over price hikes on a cancer drug, during a congressional hearing on Wednesday.
  • Porter, alongside freshman congresswomen Rep. Rashida Tlaib and Rep. Ayanna Pressley, grilled the CEOs of Teva, Celgene, and Bristol-Myers Squibb as part of a House Oversight Committee investigation into the pricing of Teva’s Multiple Sclerosis drug Copaxone and Bristol-Myers Squibb’s multiple myeloma drug Revlimid. 
  • During the congressional hearing, Porter, a former consumer protection attorney, tore into Alles, writing key figures in her questions — such as how much the CEO makes, how much a single pill of Revlimid cost over the years, and how much his bonus was as a result
Read More

The global “cancer biomarkers market size” is forecast to reach USD 48.20 billion by 2026 on account of the increasing popularity of personalized treatment for cancer worldwide. Biomarkers help to detect cancer at an early stage and facilitate noninvasive diagnosis at high-speed by utilizing different proteomic and genomic markers. As per a recently published report by Fortune Business insights™ titled, “Cancer Biomarkers Market Size, Share & Industry Analysis, By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer And Others), By Biomarker Type (PSA, HER-2, EGFR, KRAS, and others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026,” the market size was USD 18.94 billion in 2018 and will exhibit a CAGR of 12.4% between 2019 and 2026.

Highlights of the Report:

  • In-depth analysis of various insights, namely, Cancer Biomarkers Market trends, growth drivers, opportunities, and
Read More

In the passing away of economist Isher Judge Ahluwalia, the country has lost an institution builder, a good academic, and a person who was passionate about good quality research and data analysis. More than this, she was an affable person who had a good memory to remember all those she met and interacted with during her career, said people who knew her well and worked closely over the last four decades.

Isher, as she was known to all, died on Saturday after a 10-month fight with brain cancer. She would have turned 75 on October 1.  A PhD from the Massachusetts Institute of Technology (MIT), a MA from the Delhi School of Economics and a BA (Eco Homs) from Presidency College, Kolkata, Isher was a Padma Bhushan awardee who described her modest “Hindi medium” origins in her recently released memoirs, Breaking Through.

“She was the best human being you can

Read More

WASHINGTON, Sept. 23, 2020 /PRNewswire/ — Patient group ALK Positive and LUNGevity Foundation today announced the three 2020 recipients of the ALK-positive Lung Cancer Research Awards. This award, driven by ALK Positive—a group that has grown to 2,000+ ALK-positive lung cancer patients and their caregivers in 50+ countries—supports high-impact research that seeks to quickly improve outcomes for the approximately 5% of non-small cell lung cancer patients who have tested positive for a mutation in the anaplastic lymphoma kinase (ALK) gene and that has the potential to transform ALK-positive lung cancer from an inevitably fatal condition into a chronic, or even curable,  condition.

The 2020 ALK-Positive Lung Cancer Research Award Program represents the second collaboration between LUNGevity Foundation, the premier private funder of lung cancer research in the U.S., and ALK Positive. The two organizations are working together to change outcomes for people diagnosed with ALK-positive lung cancer. ALK Positive

Read More

20/20 GeneSystems is the developer of diagnostic testing tools for cancer and other diseases. Keep in mind that this startup leverages AI (artificial intelligence) for its systems. Oh, and you can also invest in 20/20 GeneSystems stock through an equity crowdfunding campaign on SeedInvest.

Source: Shutterstock

The founder and CEO is Jonathan Cohen. During his career, the former patent attorney he has raised more than $15 million in equity capital for a variety of ventures. He has also been able to strike sales and marketing agreements with Fortune 500 companies like Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT) and Ping An (the largest health insurance company in China).

Key Global Partnerships

According to the investment materials from 20/20 GeneSystems, the company believes it is the only one to launch a multi-cancer screening test that is based on AI. The result is that a patient can get

Read More
/quality/85/?url=http://media.beam.usnews.com/8e/18182acc99bba58adbcf9b8e036f7c/tag:reuters.com,2020:newsml_LYNXMPEG8C0KL:12020-09-13T192408Z_1_LYNXMPEG8C0KL_RTROPTP_3_HEALTH-CORONAVIRUS-REMDESIVIR.JPG">

(Reuters) – Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint statement on Sunday.

The deal will give Gilead access to Immunomedics’ breast cancer treatment drug Trodelvy, which was granted an accelerated FDA approval in April for an aggressive and tough to treat type of breast cancer.

Gilead said it would issue a tender offer to buy all the outstanding shares of Immunomedics for $88 per share, representing a premium of about 108% over their last closing price of $42.25 on Friday.

“This acquisition represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio,” Gilead Chief Executive Officer Daniel O’Day said in a statement. “Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat.

Read More